132 related articles for article (PubMed ID: 15259790)
21. Changes in plasma apolipoprotein B-containing lipoparticle levels following therapy with fluvastatin and cholestyramine. European Fluvastatin Study Group.
Bard JM; Ose L; Hagen E; Duriez P; Pfister P; Fruchart JC; Dallongeville J
Am J Cardiol; 1995 Jul; 76(2):65A-70A. PubMed ID: 7604802
[TBL] [Abstract][Full Text] [Related]
22. High-dose fluvastatin and bezafibrate combination treatment for heterozygous familial hypercholesterolemia.
Eliav O; Schurr D; Pfister P; Friedlander Y; Leitersdorf E
Am J Cardiol; 1995 Jul; 76(2):76A-79A. PubMed ID: 7604804
[TBL] [Abstract][Full Text] [Related]
23. Open-label study to assess the efficacy, safety, and tolerability of fluvastatin versus bezafibrate for hypercholesterolemia.
Fanghänel G; Espinosa J; Olivares D; Sánchez L; Morales M; Martínez L; Macías G; Valdés E; Hernández G
Am J Cardiol; 1995 Jul; 76(2):57A-61A. PubMed ID: 7604800
[TBL] [Abstract][Full Text] [Related]
24. Fluvastatin and low-density lipoprotein oxidation in hypercholesterolemic renal transplant patients.
Martínez-Castelao A; Grinyó JM; Fiol C; Castiñeiras MJ; Hurtado I; Gil-Vernet S; Serón D; Porta I; Miñarro A; Villarroya A; Alsina J
Kidney Int Suppl; 1999 Jul; 71():S231-4. PubMed ID: 10412785
[TBL] [Abstract][Full Text] [Related]
25. Efficacy of fluvastatin, a totally synthetic 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor. FLUENT Study Group. Fluvastatin Long-Term Extension Trial.
Zavoral JH; Haggerty BJ; Winick AG; Bergmann SD
Am J Cardiol; 1995 Jul; 76(2):37A-40A. PubMed ID: 7604795
[TBL] [Abstract][Full Text] [Related]
26. Fluvastatin with and without niacin for hypercholesterolemia.
Jacobson TA; Chin MM; Fromell GJ; Jokubaitis LA; Amorosa LF
Am J Cardiol; 1994 Jul; 74(2):149-54. PubMed ID: 8023779
[TBL] [Abstract][Full Text] [Related]
27. A preliminary report of the safety and efficacy of fluvastatin for hypercholesterolemia in renal transplant patients receiving cyclosporine.
Goldberg RB; Roth D
Am J Cardiol; 1995 Jul; 76(2):107A-109A. PubMed ID: 7604782
[TBL] [Abstract][Full Text] [Related]
28. Comparison of lipid-lowering effects of low-dose fluvastatin and conventional-dose gemfibrozil in patients with primary hypercholesterolemia.
Betteridge DJ; Durrington PN; Fairhurst GJ; Jackson G; McEwan MS; McInnes GT; Miller JP; Mir MA; Reckless JP; Rees-Jones DI
Am J Med; 1994 Jun; 96(6A):45S-54S. PubMed ID: 8017467
[TBL] [Abstract][Full Text] [Related]
29. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1994 Dec; (77):28-32. PubMed ID: 19496270
[TBL] [Abstract][Full Text] [Related]
30. Fluvastatin in combination with other lipid-lowering agents.
Jokubaitis LA
Br J Clin Pract Suppl; 1996 Jan; 77A():28-32. PubMed ID: 8729588
[TBL] [Abstract][Full Text] [Related]
31. Reduced susceptibility of low density lipoprotein (LDL) to lipid peroxidation after fluvastatin therapy is associated with the hypocholesterolemic effect of the drug and its binding to the LDL.
Hussein O; Schlezinger S; Rosenblat M; Keidar S; Aviram M
Atherosclerosis; 1997 Jan; 128(1):11-8. PubMed ID: 9051193
[TBL] [Abstract][Full Text] [Related]
32. A multicenter, randomized, double-blind clinical trial comparing the low-density lipoprotein cholesterol-lowering ability of lovastatin 10, 20, and 40 mg/d with fluvastatin 20 and 40 mg/d.
Davidson MH; Palmisano J; Wilson H; Liss C; Dicklin MR
Clin Ther; 2003 Nov; 25(11):2738-53. PubMed ID: 14693301
[TBL] [Abstract][Full Text] [Related]
33. Effects of fluvastatin extended-release (80 mg) alone and in combination with ezetimibe (10 mg) on low-density lipoprotein cholesterol and inflammatory parameters in patients with primary hypercholesterolemia: a 12-week, multicenter, randomized, open-label, parallel-group study.
Alvarez-Sala LA; Cachofeiro V; Masana L; Suarez C; Pinilla B; Plana N; Trias F; Moreno MA; Gambus G; Lahera V; Pintó X
Clin Ther; 2008 Jan; 30(1):84-97. PubMed ID: 18343245
[TBL] [Abstract][Full Text] [Related]
34. Lowering effects of four different statins on serum triglyceride level.
Branchi A; Fiorenza AM; Rovellini A; Torri A; Muzio F; Macor S; Sommariva D
Eur J Clin Pharmacol; 1999 Sep; 55(7):499-502. PubMed ID: 10501818
[TBL] [Abstract][Full Text] [Related]
35. Fluvastatin and niacin in hypercholesterolemia: a preliminary report on gender differences in efficacy.
Jacobson TA; Jokubaitis LA; Amorosa LF
Am J Med; 1994 Jun; 96(6A):64S-68S. PubMed ID: 8017469
[TBL] [Abstract][Full Text] [Related]
36. The association of common SNPs and haplotypes in the CETP and MDR1 genes with lipids response to fluvastatin in familial hypercholesterolemia.
Bercovich D; Friedlander Y; Korem S; Houminer A; Hoffman A; Kleinberg L; Shochat C; Leitersdorf E; Meiner V
Atherosclerosis; 2006 Mar; 185(1):97-107. PubMed ID: 16002074
[TBL] [Abstract][Full Text] [Related]
37. Conversion from fluvastatin to simvastatin therapy at a dose ratio of 8 to 1: effect on serum lipid levels and cost.
Rindone JP; Arriola G
Clin Ther; 1998; 20(2):340-6. PubMed ID: 9589824
[TBL] [Abstract][Full Text] [Related]
38. Effect of fluvastatin for safely lowering atherogenic lipids in renal transplant patients receiving cyclosporine.
Holdaas H; Hartmann A; Stenstrøm J; Dahl KJ; Borge M; Pfister P
Am J Cardiol; 1995 Jul; 76(2):102A-106A. PubMed ID: 7604781
[TBL] [Abstract][Full Text] [Related]
39. Effect of fluvastatin or bezafibrate on the distribution of high density lipoprotein subpopulations in patients with familial hypercholesterolemia.
Hailer S; Pogarell O; Keller C; Wolfram G
Arzneimittelforschung; 1996 Sep; 46(9):879-83. PubMed ID: 8876936
[TBL] [Abstract][Full Text] [Related]
40. Effects of fluvastatin on human biliary lipids.
Tazuma S; Ohya T; Mizuno T; Takizawa I; Kunita T; Takata K; Hayashi K; Hino F; Tokumo H; Watanabe T
Am J Cardiol; 1995 Jul; 76(2):110A-113A. PubMed ID: 7604783
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
